Log In
Print
BCIQ
Print
Print this Print this
 

Vimizim, elosulfase alfa (BMN 110) (formerly BMN-110, GALNS)

  Manage Alerts
Collapse Summary General Information
Company BioMarin Pharmaceutical Inc.
DescriptionRecombinant human N-acetylgalactosamine-6-sulfatase
Molecular Target
Mechanism of ActionEnzyme replacement therapy
Therapeutic ModalityBiologic: Enzyme
Latest Stage of DevelopmentMarketed
Standard IndicationMucopolysaccharidosis
Indication DetailsTreat mucopolysaccharidosis IVA (MPS IVA, Morquio's syndrome)
Regulatory Designation U.S. - Orphan Drug (Treat mucopolysaccharidosis IVA (MPS IVA, Morquio's syndrome));
U.S. - Priority Review (Treat mucopolysaccharidosis IVA (MPS IVA, Morquio's syndrome));
EU - Orphan Drug (Treat mucopolysaccharidosis IVA (MPS IVA, Morquio's syndrome));
EU - Standard Review (Treat mucopolysaccharidosis IVA (MPS IVA, Morquio's syndrome));
Japan - Orphan Drug (Treat mucopolysaccharidosis IVA (MPS IVA, Morquio's syndrome));
Canada - Standard Review (Treat mucopolysaccharidosis IVA (MPS IVA, Morquio's syndrome))
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$48.5M

$48.5M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today